NICE(UK): Isatuximab plus pomalidomide and dexamethasone can be used as an option to treat relapsed and refractory multiple myeloma in adults if: i) they have had 3 previous… read more.
Novocure announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Optune Pax for the treatment of adult patients diagnosed with unresectable locally advanced pancreatic cancer, concomitant… read more.
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued nineteen positive recommendations between 17 and 21 September 2026, spanning oncology, rheumatology, dermatology, neurology,… read more.
The National Institute for Health and Care Excellence (NICE) has issued four Technology Appraisal decisions in September 2026, comprising three positive first recommendations and one negative decision. Decisions… read more.
Mirum Pharmaceuticals, Inc. and Incyte announced that the FDA has approved Atebrioz (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric… read more.
Johnson & Johnson announced new findings on IMAAVY (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG) across 15 novel abstracts to be presented at the 2026 Myasthenia… read more.
Medtronic announced regulatory milestones for software used with two cardiac ablation platforms. This includes FDA clearance and CE Mark for the latest Affera Prism-2 Mapping Software. The company… read more.
Vanda Pharmaceuticals Inc. announced positive topline results from its pivotal Phase III study of Hetlioz (tasimelteon) 20 mg in adults with Delayed Sleep-Wake Phase Disorder (DSWPD). Vanda intends… read more.
Bristol Myers Squibb announced that the FDA approved CAMZYOS (mavacamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms in adults and… read more.
Eli Lilly and Company announced results from a new analysis showing that Foundayo (orforglipron) 17.2 mg was associated with significantly greater weight loss and better blood sugar control… read more.
AbbVie announced that the FDA has approved JUVMO (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for the treatment of adults with Parkinson’s disease, a progressive… read more.
JCR Pharmaceuticals Co., Ltd. announced that the Ministry of Health, Labour and Welfare of Japan granted orphan drug designation to givinostat, an investigational drug for the treatment of… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
